الصفحة الرئيسية>>Peptides>>ATI-2341 TFA

ATI-2341 TFA

رقم الكتالوجGC38541

ATI-2341 عبارة عن ناهض خيفي قوي وانتقائي وظيفيًا من النوع 4 لمستقبلات كيميائية C-X-C (CXCR4) ، والذي يعمل بمثابة رابط متحيز ، ويفضل تنشيط Gαi على Gα13

Products are for research use only. Not for human use. We do not sell to patients.

ATI-2341 TFA التركيب الكيميائي

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
1622٫00
متوفر
1mg
143٫00
متوفر
5mg
398٫00
متوفر
10mg
622٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs)[1][2].

CXCR4[1]

[1]. Quoyer J, et al. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):E5088-97. [2]. Tchernychev B, et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22255-9.

مراجعات

Review for ATI-2341 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ATI-2341 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.